Access cutting-edge autoimmune liver disease treatment through this clinical trial at a research site in Cincinnati. Study-provided care at no cost to qualified participants.
Quick Self-Assessment
See if you qualify for this Cincinnati location
Preparing your pre-screening questions…
Access autoimmune liver disease specialists at no cost
This study follows strict safety protocols and ethical guidelines
All study-related autoimmune liver disease treatment provided free
Check if you qualify for this autoimmune liver disease clinical trial in Cincinnati, OH
No-Cost Study Care
Local to Cincinnati
Convenient for OH residents
Cutting-Edge Treatment
Access to innovative therapies
Expert Medical Care
Close monitoring by specialists
Possible Compensation*
For time and travel
*Compensation varies by study. Confirm details with coordinator.
Autoimmune liver diseases (AILD), which include Primary Sclerosing Cholangitis (PSC) and Autoimmune Hepatitis (AIH) are a common etiological factor for chronic liver disease among adolescents. This is a longitudinal study to identify surrogate endpoints with an accurate predictive value for the progression of hepatobiliary damage in subjects with pediatric onset AILD. This study will involve collection of MRI-based data at the time of enrollment and at year 1 and 2 of follow up, and collection of clinical data for 10 years following enrollment. There is a strong possibility that MRI quantitative techniques may be more sensitive to disease progression than standard clinical and laboratory tests. To investigate predictivity of MRI based biomarkers, summary measures of MRCP/MREL from baseline, Year 1 and Year 2, e.g. change rate, maximum, and average will be calculated as predictors for Year 10 clinical outcomes. The same predictors will also be used to model native liver survival in a proportional hazard regression. Findings from this study may be used to assess disease progression and to predict complications and survival of liver disease patients.
Sponsor: Children's Hospital Medical Center, Cincinnati
Yes, this clinical trial (NCT03178630) has an active research site in Cincinnati, OH that is currently enrolling participants.
Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.
Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.
Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.
If you're searching for autoimmune liver disease treatment options in Cincinnati, OH, this clinical trial (NCT03178630) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our Cincinnati research site is actively enrolling participants for this clinical trial. You'll receive care from experienced autoimmune liver disease specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.
Looking for more options? Browse all autoimmune liver disease clinical trials near you to find additional studies recruiting in your area.
See all multiple myeloma clinical trials recruiting in Cincinnati — not just this study.
Browse Multiple Myeloma Trials in Cincinnati →